{
    "ALK Rearrangement Positive (Progression)": {
        "Asymptomatic": {
            "Continue Alectinib/Brigatinib/Lorlatinib": "Progression (See NSCL-22)"
        },
        "Symptomatic Brain Metastases": {
            "Local Therapy (SRS/WBRT)": "Continue ALK Inhibitor (See NSCL-22)"
        },
        "Symptomatic Systemic Progression": {
            "Lorlatinib (if not previously given)": "Progression (See NSCL-22)",
            "Chemotherapy": "Progression (See NSCL-22)"
        }
    },
    "footnotes": {
        "1": "See Principles of Systemic Therapy (NSCL-F)."
    }
}